MT1G hypermethylation: A potential prognostic marker for hepatoblastoma

Pediatric Research

Volumn 67, Issue 4, 2010, Pages 387-393

  Sakamoto, Luis H T ^a   De Camargo, Beatriz ^b   Cajaiba, Mariana ^b   Soares, Fernando A ^b   Vettore, Andréi L ^a,c  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; CALCITONIN RELATED POLYPEPTIDE ALPHA; CYCLIN A1; CYCLIN D2; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DEATH ASSOCIATED PROTEIN KINASE; ESTROGEN RECEPTOR ALPHA; GLUTATHIONE TRANSFERASE P1; METALLOTHIONEIN 1G; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE 2; PROTEIN AIM1; PROTEIN MINT31; PROTEIN MLH1; PROTEIN RB1; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; SECRETED FRIZZLED RELATED PROTEIN 1; SECRETOGLOBIN FAMILY 3A MEMBER 1; SUPPRESSOR OF CYTOKINE SIGNALING 1; THROMBOSPONDIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE IDENTIFICATION; HEPATOBLASTOMA; HUMAN; HUMAN TISSUE; INFANT; MALE; NEWBORN; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DNA METHYLATION; FEMALE; HEPATOBLASTOMA; HUMANS; INFANT; INFANT, NEWBORN; KAPLAN-MEIERS ESTIMATE; LIVER NEOPLASMS; MALE; METALLOTHIONEIN; PROGNOSIS; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 77949566249     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1203/PDR.0b013e3181d01863     Document Type: Article

References (43)

1. Aronson DC, Schnater JM, Staalman CR, Weverling GJ, Plaschkes J, Perilongo G, Brown J, Phillips A, Otte JB, Czauderna P, MacKinlay G, Vos A 2005 Predictive value of the pretreatment extent of disease system in hepatoblastoma: results from the International Society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 study. J Clin Oncol 23:1245-1252
2. Herzog CE, Andrassy RJ, Eftekhari F 2000 Childhood cancers: hepatoblastoma. Oncologist 5:445-453
3. Fuchs J, Rydzynski J, Von Schweinitz D, Bode U, Hecker H, Weinel P, Bürger D, Harms D, Erttmann R, Oldhafer K, Mildenberger H; Study Committee of the Cooperative Pediatric Liver Tumor Study Hb 94 for the German Society for Pediatric Oncology and Hematology 2002 Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer 95:172-182
4. Schnater JM, Köhler SE, Lamers WH, von Schweinitz D, Aronson DC 2003 Where do we stand with hepatoblastoma? A review. Cancer 98:668-678
5. Herman JG, Baylin SB 2003 Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042-2054
6. Garinis GA, Patrinos GP, Spanakis NE, Menounos PG 2002 DNA hypermethyl-ation: when tumour suppressor genes go silent. Hum Genet 111:115-127
7. Laird PW 2003 The power and the promise of DNA methylation markers. Nat Rev Cancer 3:253-266
8. Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su HH, Petrelli NJ, Zhang X, O'Dorisio MS, Held WA, Cavenee WK, Plass C 2000 Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24:132-138
9. Esteller M, Corn PG, Baylin SB, Herman JG 2001 A gene hypermethylation profile of human cancer. Cancer Res 61:3225-3229
10. Harada K, Toyooka S, Maitra A, Maruyama R, Toyooka KO, Timmons CF, Tomlinson GE, Mastrangelo D, Hay RJ, Minna JD, Gazdar AF 2002 Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene 21:4345-4349
11. Shim YH, Park HJ, Choi MS, Kim JS, Kim H, Kim JJ, Jang JJ, Yu E 2003 Hypermethylation of the p16 gene and lack of p16 expression in hepatoblastoma. Mod Pathol 16:430-436
12. Nagai H, Naka T, Terada Y, Komazaki T, Yabe A, Jin E, Kawanami O, Kishimoto T, Konishi N, Nakamura M, Kobayashi Y, Emi M 2003 Hypermethylation associated with inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human hepatoblastomas. J Hum Genet 48:65-69
13. Vidal DO, Paixao VA, Brait M, Souto EX, Caballero OL, Lopes LF, Vettore AL 2007 Aberrant methylation in pediatric myelodysplastic syndrome. Leuk Res 31:175-181
14. Eads CA, Lord RV, Wickramasinghe K, Long TI, Kurumboor SK, Bernstein L, Peters JH, DeMeester SR, DeMeester TR, Skinner KA, Laird PW 2001 Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 61:3410-3418
15. Carvalho AL, Jeronimo C, Kim MM, Henrique R, Zhang Z, Hoque MO, Chang S, Brait M, Nayak CS, Jiang WW, Claybourne Q, Tokumaru Y, Lee J, Goldenberg D, Garrett-Mayer E, Goodman S, Moon CS, Koch W, Westra WH, Sidransky D, Califano JA 2008 Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res 14:97-107
16. Lehmann U, Länger F, Feist H, Glöckner S, Hasemeier B, Kreipe H 2002 Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol 160:605-612
17. Harden SV, Tokumaru Y, Westra WH, Goodman S, Ahrendt SA, Yang SC, Sidransky D 2003 Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res 9:1370-1375
18. Jerónimo C, Usadel H, Henrique R, Oliveira J, Lopes C, Nelson WG, Sidransky D 2001 Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst 93:1747-1752
19. Fackler MJ, McVeigh M, Mehrotra J, Blum MA, Lange J, Lapides A, Garrett E, Argani P, Sukumar S 2004 Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res 64:4442-4452
20. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, Koh H, Simms L, Barker M, Leggett B, Levine J, Kim M, French AJ, Thibodeau SN, Jass J, Haile R, Laird PW 2006 CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38:787-793
21. Hoque MO, Topaloglu O, Begum S, Henrique R, Rosenbaum E, Van Criekinge W, Westra WH, Sidransky D 2005 Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol 23:6569-6575
22. Müller HM, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, Perkmann E, Marth C, Widschwendter M 2003 DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res 63:7641-7645
23. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, Laird PW 2000 MethyLight: a high-throughput assay to measure DNA meth-ylation. Nucleic Acids Res 28:E32
24. Roebuck DJ, Aronson D, Clapuyt P, Czauderna P, de Ville de Goyet J, Gauthier F, Mackinlay G, Maibach R, McHugh K, Olsen OE, Otte JB, Pariente D, Plaschkes J, Childs M, Perilongo G; International Childhood Liver Tumor Strategy Group 2007
25. PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group. Pediatr Radiol 37:123-132, 2005
26. Czauderna P, Otte JB, Aronson DC, Gauthier F, MacKinlay G, Roebuck D, Plaschkes J, Perilongo G 2005 Guidelines for surgical treatment of hepatoblastoma in the modern era\recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL). Eur J Cancer 41:1031-1036
27. Fukuzawa R, Umezawa A, Ochi K, Urano F, Ikeda H, Hata J 1999 High frequency of inactivation of the imprinted H19 gene in "sporadic" hepatoblastoma. Int J Cancer 82:490-497
28. Sugawara W, Haruta M, Sasaki F, Watanabe N, Tsunematsu Y, Kikuta A, Kaneko Y 2007 Promoter hypermethylation of the RASSF1A gene predicts the poor outcome of patients with hepatoblastoma. Pediatr Blood Cancer 49:240-249
29. Tsou JA, Galler JS, Siegmund KD, Laird PW, Turla S, Cozen W, Hagen JA, Koss MN, Laird-Offringa IA 2007 Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma. Mol Cancer 6:70
30. Wang YC, Yu ZH, Liu C, Xu LZ, Yu W, Lu J, Zhu RM, Li GL, Xia XY, Wei XW, Ji HZ, Lu H, Gao Y, Gao WM, Chen LB 2008 Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients. World J Gastroenterol 14:3074-3080
31. Yeo W, Wong WL, Wong N, Law BK, Tse GM, Zhong S 2005 High frequency of promoter hypermethylation of RASSF1A in tumorous and non-tumourous tissue of breast cancer. Pathology 37:125-130
32. Koul S, McKiernan JM, Narayan G, Houldsworth J, Bacik J, Dobrzynski DL, Assaad AM, Mansukhani M, Reuter VE, Bosl GJ, Chaganti RS, Murty VV 2004 Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors. Mol Cancer 3:16
33. Foulkes WD 1995 A tale of four syndromes: familial adenomatous polyposis, Gardner syndrome, attenuated APC and Turcot syndrome. QJM 88:853-863
34. Barber M, Murrell A, Ito Y, Maia AT, Hyland S, Oliveira C, Save V, Carneiro F, Paterson AL, Grehan N, Dwerryhouse S, Lao-Sirieix P, Caldas C, Fitzgerald RC
35. Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer. J Pathol 216:295-306, 2008
36. Fujii S, Ochiai A 2008 Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells. Cancer Sci 99:738-746
37. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, Mehra R, Laxman B, Cao X, Yu J, Kleer CG, Varambally S, Chinnaiyan AM 2008 Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 27:7274-7284
38. Blaker H, Hofmann WJ, Rieker RJ, Penzel R, Graf M, Otto HF 1999 Beta-catenin accumulation and mutation of the CTNNB1 gene in hepatoblastoma. Genes Chromosomes Cancer 25:399-402
39. Park WS, Oh RR, Park JY, Kim PJ, Shin MS, Lee JH, Kim HS, Lee SH, Kim SY, Park YG, An WG, Kim HS, Jang JJ, Yoo NJ, Lee JY 2001 Nuclear localization of beta-catenin is an important prognostic factor in hepatoblastoma. J Pathol 193:483-490
40. Wu SJ, Yao M, Chou WC, Tang JL, Chen CY, Ko BS, Huang SY, Tsay W, Chen YC, Shen MC, Wang CH, Yeh YC, Tien HF 2006 Clinical implications of SOCS1 methylation in myelodysplastic syndrome. Br J Haematol 135:317-323
41. Jahroudi N, Foster R, Price-Haughey J, Beitel G, Gedamu L 1990 Cell-type specific and differential regulation of the human metallothionein genes. Correlation with DNA methylation and chromatin structure. J Biol Chem 265:6506-6511
42. Nagata T, Takahashi Y, Ishii Y, Asai S, Nishida Y, Murata A, Koshinaga T, Fukuzawa M, Hamazaki M, Asami K, Ito E, Ikeda H, Takamatsu H, Koike K, Kikuta A, Kuroiwa M, Watanabe A, Kosaka Y, Fujita H, Miyake M, Mugishima H 2003 Transcriptional profiling in hepatoblastomas using high-density oligonucleotide DNA array. Cancer Genet Cytogenet 145:152-160
43. Henrique R, Jeronimo C, Hoque MO, Nomoto S, Carvalho AL, Costa VL, Oliveira J, Teixeira MR, Lopes C, Sidransky D 2005 MT1G hypermethylation is associated with higher tumor stage in prostate cancer. Cancer Epidemiol Biomarkers Prev 14:1274-1278